Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content
Regulatory
22 February 2023

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllAnnual reportInterim ReportNewsNewsletterPress releaseYear end reportRegulatory posts
22 February 2023 Scandion Oncology – Q4 & year-end report 2022 Download Presentation Webcast Workbook
16 November 2022 Scandion Oncology – Interim Report Q3 2022 Download Presentation Webcast Workbook
25 August 2022 Scandion Oncology – Interim Report Q2 2022 Download Presentation Webcast Workbook
19 May 2022 Scandion Oncology – Interim Report Q1 2022 Download Presentation Webcast Workbook
17 February 2022 Scandion Oncology announces its results for the fourth quarter and year-end 2021 Download Presentation Webcast Workbook
18 November 2021 Scandion Oncology A/S announces its results for the third quarter of 2021 Download Presentation Webcast Workbook
19 August 2021 Scandion Oncology A/S announces its results for the first half year of 2021 Download Presentation Webcast Workbook
20 May 2021 Q1 2021 Report: Scandion Oncology is evolving Download Presentation Webcast Workbook
18 February 2021 Year-end Report 2020: Scandion Oncology is poised for the future Download Presentation Webcast Workbook
19 November 2020 Interim Report 1 January 2020 – 30 September 2020 Download Presentation Webcast Workbook
20 August 2020 Half-Year Report 1 January 2020 – 30 June 2020 Download Presentation Webcast Workbook
21 May 2020 Interim report 1 January – 31 March 2020 Download Presentation Webcast Workbook
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.